- Home
- RMR vs ACIU Comparison
RMR vs ACIU Comparison
Compare RMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMR | ACIU |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.0M | 288.0M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RMR | ACIU |
|---|---|---|
| Price | $20.29 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | 168.5K | ★ 255.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $700,284,000.00 | N/A |
| Revenue This Year | $259.61 | $706.75 |
| Revenue Next Year | $2.45 | $321.13 |
| P/E Ratio | $26.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.27 | $1.60 |
| 52 Week High | $20.48 | $4.00 |
Technical Indicators
Market Signals| Indicator | RMR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 71.20 | 46.57 |
| Support Level | $14.72 | $2.58 |
| Resistance Level | $20.48 | $2.99 |
| Average True Range (ATR) | 0.58 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 87.56 | 37.00 |
Price Performance
Historical ComparisonAbout RMR The RMR Group Inc.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company with a primary focus on commercial real estate and related businesses in the United States. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. The company manages a diverse portfolio of real estate assets across sectors such as office, industrial, healthcare, retail, and hospitality, etc. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company derives the majority of its revenues from its provision of management services.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.